AstraZeneca in broad drug deal with Bicycle worth up to $1 bln
December 01, 2016 at 07:42 AM EST
LONDON, Dec 1 (Reuters) - AstraZeneca has signed a wide-ranging deal with private biotech firm Bicycle Therapeutics to develop a novel class of small molecule medicines for treating respiratory, cardiovascular and metabolic diseases.
